Pfizer reports positive top-line result of Phase III S-TRAC Trial of Sutent to treat RCC
US-based pharmaceutical company Pfizer has reported positive top-line results of the Phase III S-TRAC clinical trial of Sutent against placebo to treat patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Pfizer | Pharmaceuticals | Renal Cell Carcinoma